Current Report Filing (8-k)
August 26 2020 - 7:31AM
Edgar (US Regulatory)
0001061983
false
0001061983
2020-08-26
2020-08-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): August
26, 2020
Cytokinetics, Incorporated
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
000-50633
|
94-3291317
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification Number)
|
280
East Grand Avenue, South San
Francisco, California 94080
|
(Address of Principal Executive Offices) (Zip Code)
|
(650) 624-3000
(Registrant’s
telephone number, including area code)
Not Applicable
(Former name or former
address, if changed since last report)
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
CYTK
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
Cytokinetics, Incorporated (the “Registrant”
or “Cytokinetics”) and Cure SMA today announced the renewal of their partnership to increase education, awareness,
public policy and fundraising for spinal muscular atrophy (“SMA”). Cytokinetics will lend support for several of Cure
SMA’s upcoming initiatives across the United States and continues as a member of the Cure SMA Industry Collaboration, a partnership
between Cure SMA and pharmaceutical companies to address topics critical to advancing drug development in SMA. Cytokinetics remains
committed to serving those living with SMA, a genetic disease that robs people of their physical strength and can take away their
ability to walk, eat or breathe.
Cytokinetics will sponsor two events to
help fundraise and increase awareness of SMA in the local community. In September, Cytokinetics will participate as a sponsor of
the Virtual Walk-n-Roll program where SMA families will be walking and rolling around their neighborhoods for Cure SMA. Then, in
October, Cytokinetics will support Cure SMA’s Evening of Hope: A Virtual Masquerade, an evening of inspiration, celebration,
and hope uniting the SMA community across the country.
Additionally, Cytokinetics is pleased to
continue its membership in the Cure SMA Industry Collaboration, which brings together pharmaceutical companies, Cure SMA, and other
non-profit organizations, to address critical issues related to advancing drug development in SMA. Cytokinetics is actively involved
in topic groups focused on regulatory affairs, clinical trials and patient reported data.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CYTOKINETICS, INCORPORATED
|
|
|
|
|
|
|
Date: August 26, 2020
|
By:
|
/s/ Ching Jaw
|
|
|
Ching Jaw
|
|
|
Senior Vice President, Chief Financial Officer
|
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2023 to Sep 2024